Work package 2: Disease understanding and outcome definition

WP2 will develop standardised definitions of prioritised prostate cancer outcomes and diagnostic and prognostic factors across the different stages of prostate care, whilst taking into account existing heterogeneity in data collection and the disease itself. WP2 aims to directly inform guideline development and clinical practice by standardising definitions and terminology regarding diagnosis, prognosis and outcomes for prostate cancer. The most important outcomes for different stakeholders will be prioritised and defined and a core outcome set will be developed for different stages of the disease. For each of the outcomes identified as core, the most appropriate and feasible outcome measurement instrument will be recommended. Consensus will also be sought for diagnostic tests and parameters, and prognostic factors. WP2 will feed into WP3, 4 and 5, whilst the results from WP4/WP5 will feedback into WP2.

Objectives:

Identify core outcome sets and diagnostic and prognostic factors for localised, locally advanced, and advanced-metastatic prostate cancer in the context of the patient’s treatment pathway, including quality of life, patient-reported outcomes and economic endpoints.
Assess how these outcomes and diagnostic and prognostic factors should be prioritised and recommend a valid and feasible outcome measurement instrument for each of the outcomes.
Disseminate findings and guidelines to health practitioners and patients to improve management and care of men with prostate cancer in close collaboration with WP7.

WP2 Partners

European Association of Urology, King’s College London, Universita Vita-Salute San Raffaele, International Consortium for Health Outcomes Measurement, University of Aberdeen, European Organisation for Research and Treatment of Cancer, Bayer, Sanofi, Janssen Pharmaceutical, Orion Corporation and Astellas Pharma.